Most collagen fillers will be gone from the market at year’s end reports the latest issue of Dermatology Times.
Late last year Johnson & Johnson announced that it was discontinuing its collagen filler Evolence, and in January Allergan announced it would be discontinuing its collagen fillers at the end of the year. Allergan halted production of the products in 2009, but manufactured enough inventory to meet estimated market demand through the end of 2010, according to Kelly Lao, manager of corporate communications.
Patients who have received treatment with Evolence will continue to receive support regarding medical inquiries or reporting of adverse reactions.
As for Allergan’s collagen fillers, which includes CosmoPlast, CosmoDerm and bovine products Zyderm and Zyplast, Lao explains that “the discontinuation of the sale of our collagen products … is in response to declined market interest … since the introduction of hyaluronic acid dermal fillers like Juvéderm have become more popular.”
Seth L. Matarasso, M.D., clinical professor of dermatology at the University of California School of Medicine, San Francisco, agrees with Lao’s assessment. “There is an overwhelming popularity of the new kid on the block: the hyaluronic acids. They have been embraced universally, and suddenly collagens aren’t as popular,” he says.
Hyaluronic acid products have several advantages, including:
- Longer-lasting results
- Appear to give a better fill
- Some contain lidocaine for less painful injections
Future improvements will allow hyaluronic acids to provide more volume and contour-changing ability and the ability to fill deeper lines, reports Dermatology Times.
Advancements in Dermatology and Skin Speaks Spa M.D. offer the following hyaluronic acids fillers: Juvéderm, Restylane, Radiesse, and Sculptra.
The full story is available online: “Dermatologists prepare for departure of collagen from U.S. market.”
